4-Antibody appoints ceo and new board member

To develop more partnerships with corporate pharma

Swiss antibody specialist 4-Antibody has appointed Robert Burns as chief executive and Thomas von Rüden to its board of directors.

Burns has previously held senior positions in the antibody area as ceo of Oslo, Norway-based Affitech and Celldex Therapeutics in the US.

Max Burger, 4-Antibody’s chairman, said Burns is a deal-maker and has the experience to drive 4-Antibody forward to achieve additional multi-target collaborations with corporate pharma to add to the partnership recently put in place with Boehringer Ingelheim.

Von Rüden was formerly ceo at Direvo Industrial Biotechnology in Cologne, Germany. Prior to this, he was chairman of Direvo’s Advisory Board and worked as president and ceo at Direvo Biotech until Bayer Schering acquired the company in September 2008.

Von Rüden also spent six years as cso and executive VP of Business Development with MorphoSys in Munich. Before that he was director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna.

‘We expect Thomas’s knowledge of key trends in pharma antibody discovery and development to add incremental momentum to our pursuit of new corporate partnerships as well as our internal drug discovery and development programmes,’ said Burns.

You may also like

Ingredients

4-Antibody to collaborate with HGS

To discover and develop fully human therapeutic antibodies
Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Long-term collaboration for targets in various disease indications
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Subscribe now